Determination of Regulatory Review Period for Purposes of Patent Extension; NeutrexinTM

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for NeutrexinTM, a human drug product, and is publishing this notice as required by law. The determination was made due to the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of the patent.